Introduction & Objective: To explore the effect of mazdutide, a once-weekly GLP-1 and glucagon receptor dual agonist, on liver steatosis.

Methods: In the GLORY-1 phase 3 trial (NCT05607680), 610 Chinese adults with a BMI of 28 kg/m2 or more, or 24 kg/m2 or more and at least one weight-related comorbidity were randomly assigned 1:1:1 to receive once-weekly, subcutaneous mazdutide 4 mg, mazdutide 6 mg or placebo for 48 weeks. A subpopulation of participants had MRI scan and liver fat content (LFC) measurement by MRI-proton density fat fraction (MRI-PDFF). Change from baseline at week 48 in LFC was an exploratory endpoint of the study.

Results: In participants with baseline LFC of 5% or more and 10% or more, treatment with mazdutide 4 mg or 6 mg for 48 weeks led to marked and dose-dependent reductions in LFC. Of note, a mean relative reduction of 80.2% was achieved with mazdutide 6 mg among participant with baseline LFC of 10% or more. In participants with baseline LFC of 5% or more, compared with placebo, substantially more participants with mazdutide 4 mg and 6 mg achieved ≥30% relative reduction in LFC, ≥50% relative reduction in LFC and normalization of LFC (<5%) at week 48 (Figure).

Conclusion: In Chinese adults with overweight or obesity and liver steatosis, mazdutide 4 mg and 6 mg provides robust reductions in LFC.


L. Ji: None. H. Jiang: None. Y. Zhang: None. L. Lv: None. J. Gu: None. Z. Liu: Employee; Innovent Biologics. Y. Wang: Employee; Innoventbio. H. Deng: Employee; Innovent. L. Qian: Employee; Innoventbio.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at